During the past decade, MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 4 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim" #1 sponsor was "Celgene" with 2 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest" with 2 trials sponsored, "Dominik Paul Modest" with 1 trials sponsored and "Eli Lilly and Company" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim" #1 collaborator was "Roche Pharma AG" with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator and "German Research Foundation" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim" are "Myelodysplastic Syndromes" (3 trials), "Cholangiocarcinoma" (2 trials), "Colorectal Cancer" (2 trials), "Gallbladder Cancer" (2 trials) and "Hepatocellular Cancer" (2 trials). Many other conditions were trialed in "MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim" in a lesser frequency.

Most popular intervention types in "MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim" are "Drug" (12 trials), "Biological" (1 trials), "Diagnostic Test" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (2 trials), "Luspatercept" (2 trials), "Abemaciclib" (1 trials), "Bendamustine" (1 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim" are 15 trials for "All" genders.

Currently, there are NaN active trials in "MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim". undefined are not yet recruiting, 6 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".